Several authorities below contradict the "safe and fully reversible" statement and highlight the uncertainties and negative health impacts of puberty blockers
Agency for Health Care Administration (Florida)
The AHCA find that treatments on minors "are not consistent with widely accepted professional medical standards"
Centre for Evidence-Based Medicine (Oxford University)
The CEBM reviewed the research on puberty blockers and highlights blockers as a "momentous step in the dark"
Council for Choices in Health Care (Finland)
Finland has published advice on the medical treatment of gender dysphoric minors that contradicts New Zealand's Ministry of Health.
Irish College of General Practioners (ICGP)
The ICGP have removed statements describing puberty blockers as "reversible" from their guidelines. They now emphasise psychotherapy and highlight the lack of evidence for blockers.
Karolinska Institute (Sweden)
The Karolinska Institute has stopped giving puberty blockers to adolescents under 16. The Institute cites uncertain and extensive adverse health consequences, and the difficulties gaining informed consent.
National Association of Practising Psychiatrists (NAPP) (Australia)
NAPP advise that gender dysphoria can often be a manifestation of pre-existing family, social or psychiatric conditions. Conditions should be treated first before puberty blockers are considered.
National Health Service (UK)
The NHS has removed language indicating blockers are "fully reversible" and now states that it is "not known whether hormone blockers affect the development of the teenage brain or children's bones"
National Institute for Health and Care Excellence (NICE) (UK)
NICE have published a review of the evidence for puberty blockers. They report little or no change in mental health outcomes and a "very low" certainty of evidence.
Royal Australia New Zealand College of Psychiatrists (RANZCP)
The RANZCP advise their members that there is a "paucity of quality evidence" on outcomes for children with gender dysphoria.